Vitamin E Supplementation Greatly Reduces Risk of Cardiovascular Disease
Researchers studied 196 subjects on haemodialysis with pre-existing cardiovascular disease. They were placed on a randomised placebo controlled trial and the active treatment administered was a supplementation with 800 IU/day of vitamin E.
The subjects were followed for a median of 519 days during which the incidence of a `primary cardiovascular end-point' was monitored. This end-point was based on the presence of any of a several cardiovascular disorders, including stroke, myocardial infarction, peripheral vascular disease and angina.
The Lancet (2000;356:1213-1218) reported that Vitamin E supplementation produced a significant reduction in the risk of the primary cardiovascular disease at end-point.
Click here to Buy HGH Human Growth
Hormone |
Terms of Use - Privacy
Policy
Disclaimer: Content on this site is
for reference purposes and is not intended to substitute for
advice given by a physician, pharmacist, or other licensed
health-care professional. You should not use this information as
self-diagnosis or for treating a health problem or disease.
Links and content located on other sites is not our
responsibility. Do your own due diligence before purchasing any
product. Contact your health-care provider immediately if you
suspect that you have a medical problem. Information and
statements regarding dietary supplements have not been evaluated
by the Food and Drug Administration and are not intended to
diagnose, treat, cure, or prevent any disease or health
condition.